This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

IBio Announces New US Patent For IBioLaunch™ Technology

NEWARK, Del., Oct. 31, 2011 /PRNewswire/ -- iBio, Inc. (NYSE AMEX: IBIO) today announced notice of issuance from the United States Patent and Trademark Office for US Patent 8,058,511, entitled "System for Expression of Genes in Plants," that further extends iBio's patent coverage of viral vectors comprising its iBioLaunch™ platform. This proprietary technology owned by iBio was developed by scientists at iBio's research collaborator, the Fraunhofer USA Center for Molecular Biotechnology (Fraunhofer).

"The issuance of this patent substantially strengthens the intellectual property foundation of the iBioLaunch system for simultaneously expressing more than a single protein," said Terence Ryan, Ph.D., iBio's Senior Vice-President. "For example, this patent protects the technology we use for production of human monoclonal antibodies, a rapidly growing pharmaceutical category in which we recently announced successful product candidate testing."

iBio is commercializing its technology by establishing licenses or other collaboration arrangements both for biosimilar products and proprietary products. In January 2011, iBio and Fraunhofer entered into a License and Collaboration Agreement with Fiocruz/ Bio-Manguinhos, an entity linked to the Health Ministry of Brazil, for the development and sale of a proprietary Yellow Fever Vaccine based upon the IBioLaunch technology, to replace the chicken egg based vaccine that Fiocruz has been producing and supplying to Brazil and more than 60 other nations. Since then, iBio has been advancing and making available other candidate products based on the iBioLaunch platform for similar license and collaboration arrangements.  

The broad range of iBioLaunch-produced product candidates in clinical or preclinical development include:  (i) human alpha-galactosidase for treatment of Fabry disease, (ii) the proteins C1 esterase inhibitor and alpha-1 antitrypsin which are currently derived from human blood plasma, (iii) monoclonal antibodies, and (iv) vaccines for prevention of yellow fever, influenza, malaria and anthrax. Additional undisclosed candidates are advancing through iBio's applications research program.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,081.89 -49.97 -0.29%
S&P 500 2,014.89 +15.91 0.80%
NASDAQ 4,796.6090 -42.0340 -0.87%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs